# Bard Geesaman

> Bard Geesaman is a Series B investor at MPM Capital (Cambridge) backing Biopharma and Therapeutics. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [MPM Capital](https://shizune.co/investors/profile/mpm-capital)
- Location: Cambridge, United States
- Total investments: 5
- Last investment: Feb 2015
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/in/bgeesaman

Bard Geesaman is a Series B investor at MPM Capital in Cambridge focused on Biopharma and Therapeutics. Bard Geesaman is the Managing Director at MPM Capital.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 1 | 20% |
| Therapeutics | 1 | 20% |
| Biotechnology | 1 | 20% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 20% |
| Series C | 1 | 20% |
| Series D | 1 | 20% |
| Series E | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Chiasma | Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. Itis applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed. | $70M | Series E | Feb 27, 2015 |  |
| Chiasma | Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. Itis applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed. | $70M | Series E | Feb 27, 2015 |  |
| Chiasma | Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. Itis applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed. | $38.5M | Series D | Jul 23, 2012 |  |
| Chiasma | Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. Itis applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed. | $44M | Series C | Nov 15, 2006 |  |
| Chiasma | Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. Itis applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed. | $7.7M | Series B | Sep 12, 2005 |  |

5 of 5 investments shown.

## Co-investors
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 4 deals together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 3 deals together
- [Sofinnova Investments](https://shizune.co/investors/profile/sofinnova-ventures) — VC Fund, 2 deals together
- [F2 Ventures](https://shizune.co/investors/profile/f2-ventures) — VC Fund, 1 deal together
- [Jerusalem Global Ventures](https://shizune.co/investors/profile/jerusalem-global-ventures) — VC Fund, 1 deal together
- [MPM Capital](https://shizune.co/investors/profile/mpm-capital) — VC Fund, 1 deal together

## About MPM Capital

VC Fund · Cambridge, United States

MPM Capital is a healthcare investment firm that invests in companies developing therapeutic technologies in oncology. The company invests in life sciences companies that seek to cure diseases by translating science into clinical outcomes. The company prefers to invest in the biotechnology, healthcare, and life sciences sectors.

5 contacts available at MPM Capital.

| Name | Title | Profile |
| --- | --- | --- |
| David P. Ryan | Medical and Scientific Advisor | https://shizune.co/investors/profile/david-p-ryan |
| Detlev Biniszkiewicz | Executive Partner | https://shizune.co/investors/profile/detlev-biniszkiewicz |
| Uciane Scarlett | Principal | https://shizune.co/investors/profile/uciane-scarlett |
| Ansbert Gadicke | Managing Director and Co-Founder | https://shizune.co/investors/profile/ansbert-k-gadicke |
| Bard Geesaman | Managing Director | https://shizune.co/investors/profile/bard-geesaman |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Bard Geesaman invest in?

Bard Geesaman invests primarily in Biopharma, Therapeutics and Biotechnology startups, most often at Series B and Series C stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Bard Geesaman last invest?

The most recent investment recorded for Bard Geesaman closed in Feb 2015. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co